Lorazepam (Psychiatric/Acute Use)
Brand names: Ativan
This covers lorazepam in acute psychiatric use, a short-acting benzodiazepine used for severe anxiety and agitation, rapid tranquillisation of acute behavioural disturbance, and status epilepticus.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It enhances the inhibitory action of gamma-aminobutyric acid at the GABA-A receptor, increasing chloride conductance to produce anxiolytic, sedative and anticonvulsant effects.
Prescribing in practice
- Respiratory and central nervous system depression can be profound, especially with parenteral use or alongside opioids and other depressants, so monitor airway, breathing and sedation and have flumazenil and resuscitation facilities available during rapid tranquillisation.
- Use the lowest effective dose for the shortest time because of dependence and withdrawal risk, and avoid abrupt cessation after regular use.
- Caution in the elderly, respiratory disease, hepatic impairment and where paradoxical agitation may occur; injectable forms require appropriate dilution and monitoring.
Monitoring
During acute use monitor conscious level, respiratory rate, oxygen saturation and blood pressure, and on continued use review for tolerance and dependence.
Counselling the patient
- This medicine causes marked drowsiness; do not drive or operate machinery until fully recovered.
- Avoid alcohol and other sedatives, which dangerously increase drowsiness and breathing problems.
- Use is intended to be short term to avoid dependence.
Evidence & guidelines
NICE guidance on violence and aggression supports lorazepam as an option for rapid tranquillisation, with close monitoring of vital signs.
Reference: NICE CG137 (Epilepsies); NICE NG10 (Violence and Aggression); MHRA Clozapine Safety; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Murray Score for Acute Lung Injury (ALI/ARDS) · Respiratory Failure
- Simplified Acute Physiology Score 3 (SAPS 3) · ICU Scoring
- Killip Classification for Acute MI · Prognosis
- HEART Score for Major Adverse Cardiac Events · Chest Pain
- ADHERE Algorithm for Acute Decompensated Heart Failure · Risk Stratification
- Ottawa Heart Failure Risk Scale · Heart Failure
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185